A Canadian Prospective, Observational, Open-Label, Pharmacovigilance Study to Assess the Safety of Humate-P® Injection Volume Reduced (ivr) in Patients with Von Willebrand Disease.

医学 耐受性 不利影响 前瞻性队列研究 内科学 儿科 外科
作者
Alan Tinmouth,Victor S. Blanchette,Ramachandran Devaraj,Bruce Ritchie,David S. Barnes,Gigi van den Hoef
出处
期刊:Blood [Elsevier BV]
卷期号:114 (22): 4190-4190
标识
DOI:10.1182/blood.v114.22.4190.4190
摘要

Abstract Abstract 4190 Background Humate-P® is a plasma-derived factor VIII / von Willebrand factor concentrate. It is used for the treatment of hemophilia A and acquired factor VIII deficiency and various types of von Willebrand disease (vWD) in more than 30 countries worldwide. Humate-P® was first approved in Canada in December 2004. It is usually tolerated without reaction. In 2008, CSL Behring introduced Humate-P® ivr into Canada to replace Humate-P®. Humate-P® ivr is identical to Humate-P® except that it is reconstituted using a lower volume of diluent (Humate-P® injection volume reduced or ivr). The new lower volume preparation is identical to the currently available licensed preparation in every respect, with the exception that the diluent volume, and therefore the reconstituted volume, is 50% that of the older preparation. To ensure that the new ivr preparation was safe and well tolerated, CSL Behring Canada conducted a pharmacovigilance study designed to assess the safety and tolerability of Humate-P® ivr in patients with vWD previously treated with Humate-P®. Method Patients of any age with vWD who were previously treated with Humate-P® were enrolled in the study. Enrolled patients were treated with Humate-P® ivr according to the approved product labeling upon the recommendation of the investigator and were followed per standard of care. Patient demographic and medical history data were captured by chart review, and adverse event data and other clinical data relating to the administration of Humate-P® ivr were captured prospectively (in some cases prospective data capture was not feasible for logistical or other reasons, and the data was captured retrospectively). The efficacy of Humate-P® ivr in achieving hemostasis was evaluated by the investigator according to the following criteria: hemostasis clinically not different from normal (excellent), mildly abnormal hemostasis partial or delayed control of spontaneous bleeding or slight transient oozing from surgical wounds (good), moderately abnormal hemostasis bleeding not fully controlled but no need for additional therapy (moderate); and no improvement at all with continuation of bleeding and need for additional or alternative therapies (poor). Results A total of 21 patients (n=21) from 4 centres in Canada were enrolled and completed the study. The study population included 12 male and 9 female patients between the ages of 2 and 83. Ten patients had received Humate-P® within 1 year prior to their first Humate-P® ivr infusion. All 21 patients enrolled in the study received Humate-P® ivr per standard of care for surgery and or bleeding requiring intervention, as follows by System Organ Class: Injury, poisoning and procedural complications (n=4); Investigations (n=2); Surgical and medical procedures (n=11); and Vascular disorders (n=4; 1 case each of epistaxis, haemoptysis, rectal hemorrhage and soft tissue hemorrhage). Ten patients (47.6%) experienced at least 1 adverse event (AE). There were no individual AEs reported more than once. None of the AEs were considered to be related to Humate-P® ivr. There were no deaths reported during the study and no patient was discontinued from the study due to an AE. There were 3 serious AEs (SAEs) reported in 2 patients (n=2), including 1 cardiac arrest in a 26 year-old female (cardiac arrest due to methadone overdose). None of the 3 SAEs were considered by the investigator to be related to Humate-P® ivr. Clinical response to Humate-P® ivr was consistent with previous experience with Humate-P® in these patients, with 5 patients having a good response and 15 patients having an excellent response with Humate-P® ivr compared with 5 patients having a good response and 14 patients having an excellent response with Humate-P®. The overall clinical response in the treatment of bleeding episodes or surgeries was not available for one patient treated with Humate-P® ivr and two patients treated with Humate-P®. Conclusion Humate-P® ivr appears to be well tolerated by patients with vWD who have previously been treated with Humate-P®, with no evidence of safety issues. There is evidence of positive therapeutic experience with Humate-P® ivr similar to that observed with Humate-P®. Disclosures: Tinmouth: Canadian Blood Services: Consultancy; Novartis: Research Funding; CSL: Research Funding; Bayer: Research Funding; Wyeth: Research Funding. Blanchette:CSL - Behring: Research Funding. Ritchie:CSL Behring: Research Funding, travel costs for meetings. Barnes:CSL Behring: Employment. van den Hoef:CSL Behring: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
9月有书读发布了新的文献求助10
1秒前
2秒前
英俊的铭应助忧虑的尔容采纳,获得10
3秒前
糖糖完成签到,获得积分10
3秒前
Enoch发布了新的文献求助10
4秒前
科目三应助等待八宝粥采纳,获得10
4秒前
4秒前
亨利公爵完成签到,获得积分10
5秒前
6秒前
krenc完成签到,获得积分10
6秒前
清脆谷槐发布了新的文献求助10
7秒前
J_C_Van发布了新的文献求助10
7秒前
7秒前
江南最后的深情完成签到,获得积分10
8秒前
hr完成签到 ,获得积分10
8秒前
cckk发布了新的文献求助10
8秒前
9秒前
ca发布了新的文献求助10
9秒前
10秒前
胡萝卜发布了新的文献求助10
11秒前
11秒前
亨利公爵发布了新的文献求助10
11秒前
lzcnextdoor发布了新的文献求助10
11秒前
打打应助xcx采纳,获得10
12秒前
13秒前
shinen发布了新的文献求助30
13秒前
Barry完成签到,获得积分10
13秒前
qixiaoqi完成签到,获得积分10
14秒前
贰鸟应助QPP采纳,获得20
15秒前
lzcnextdoor完成签到,获得积分10
15秒前
冉冉完成签到 ,获得积分0
15秒前
要减肥完成签到,获得积分10
16秒前
全麦面包完成签到,获得积分10
17秒前
爱学习发布了新的文献求助10
18秒前
清脆谷槐完成签到,获得积分10
18秒前
向上的小v完成签到 ,获得积分10
18秒前
19秒前
9月有书读完成签到,获得积分10
20秒前
cola完成签到 ,获得积分10
20秒前
ca完成签到,获得积分10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds第二卷 1200
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038657
求助须知:如何正确求助?哪些是违规求助? 3576306
关于积分的说明 11375198
捐赠科研通 3306108
什么是DOI,文献DOI怎么找? 1819379
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066